R406
别名: R406 besylate
目录号:S2194 Purity: 99.43%
R406(R406 besylate) 是一种有效的 Syk 抑制剂,无细胞试验中IC50为41 nM,对Syk抑制作用强,但是不抑制Lyn,对Flt3的作用比对Syk低5倍。R406 可诱导凋亡。Phase 1。
CAS: 841290-81-1
客户使用Selleck的R406发表文献119篇
- Cell Mol Immunol, 2023 1-14.
- Cancer Cell, 2022 S1535-6108(22)00312-9
- Cancer Cell, 2021 S1535-6108(21)00492-X
- Cell, 2020 182(3):685-712.e19
- Nat Cell Biol, 2019 21(2):203-213
- Cancer Cell, 2017 31(4):549-562
- Blood, 2017 129(6):759-770
- Nat Med, 2016 22(8):915-23
- Blood, 2016 127(25):3192-201
- Nat Cell Biol, 2015 17(1):57-67
- Blood, 2015 126(16):1911-20
- Immunity, 2014 40(3):389-99
- Blood, 2014 124(4):590-7
- Blood, 2013 122(4):580-9
- Microbiol Spectr, 2025 13(1):e0254921
- Nat Commun, 2024 15(1):10599
- Nat Commun, 2024 15(1):8890
- J Clin Invest, 2024 e175147
- J Exp Clin Cancer Res, 2024 43(1):224
- J Neuroinflammation, 2024 21(1):313
- Cell Rep, 2024 43(3):113813
- Cell Rep, 2024 43(7):114454
- Cell Rep, 2024 43(3):113929
- Front Immunol, 2024 15:1425670
- Biochim Biophys Acta Mol Basis Dis, 2024 1871(3):167630
- Neurobiol Dis, 2024 201:106656
- J Inflamm Res, 2024 17:8713-8726
- BMC Cancer, 2024 24(1):399
- Cancer Res, 2023 83(2):316-331
- Front Immunol, 2023 14:1108244
- Mol Cell Proteomics, 2023 S1535-9476(23)00001-4
- J Invest Dermatol, 2023 143(3):470-479.e6
- Cells, 2023 12(5)743
- CNS Neurosci Ther, 2023 10.1111/cns.14255
- Front Med (Lausanne), 2023 10:1105538
- Res Sq, 2023 rs.3.rs-2922520
- Theranostics, 2022 12(5):2232-2247
- Redox Biol, 2022 56:102461
- Haematologica, 2022 107(8):1796-1814
- ACS Appl Mater Interfaces, 2022 14(21):24144-24159
- Free Radic Biol Med, 2022 S0891-5849(22)00004-1
- Front Immunol, 2022 13:984520
- J Virol, 2022 e0020022
- J Immunol, 2022 208(7):1664-1674
- Life Sci Alliance, 2022 5(5)e202201369
- Life Sci Alliance, 2022 5(8)e202101303
- Pathogens, 2022 12(1)53
- Dev Comp Immunol, 2022 131:104377
- Sci Transl Med, 2021 13(596)eabf8654
- Haematologica, 2021 10.3324/haematol.2021.278743
- Cell Rep, 2021 36(6):109525
- Cell Rep, 2021 34(11):108870
- Cell Mol Life Sci, 2021 10.1007/s00018-021-04009-z
- Transl Res, 2021 227:53-63
- Elife, 2021 10e65962
- Front Immunol, 2021 12:737988
- mBio, 2021 12(6):e0322821
- iScience, 2021 24(8):102871
- Int J Mol Sci, 2021 22(21)11638
- Am J Physiol Cell Physiol, 2021 320(5):C902-C915
- J Leukoc Biol, 2021 10.1002/JLB.2A0520-334R
- J Biol Chem, 2021 S0021-9258(21)00238-6
- Transl Vis Sci Technol, 2021 10(4):20
- Cell Death Dis, 2020 11(11):956
- Front Immunol, 2020 11:610523
- Int J Mol Sci, 2020 21(19)E7009
- Biomolecules, 2020 10(9)E1283
- Aging (Albany NY), 2020 7;12(9):8221-8240
- ScholarsArchive@OSU, 2020 51
- ScholarsArchive@OSU, 2020 None
- Cell Death Dis, 2019 10(8):555
- Mucosal Immunol, 2019 12(2):425-433
- Front Immunol, 2019 10:921
- PLoS Pathog, 2019 15(8):e1007923
- mBio, 2019 10(3)e00574-19
- Molecules, 2019 24(20)E3640
- J Immunol, 2019 203(12):3225-3236
- PLoS One, 2019 14(1):e0210879
- J Control Release, 2018 288:227-238
- Front Immunol, 2018 9:37
- J Bone Miner Res, 2018 33(1):167-181
- J Mol Cell Cardiol, 2018 115:82-93
- Chem Res Toxicol, 2018 31(2):127-136
- Cell Microbiol, 2018 20(2)
- Biochem Biophys Res Commun, 2018 507(1-4):217-222
- Leukemia, 2017 31(8):1686-1694
- Cancer Res, 2017 77(8):1818-1830
- Clin Immunol, 2017 175:69-74
- EMBO Rep, 2017 18(9):1604-1617
- Mol Cancer Ther, 2017 16(11):2586-2597
- Oncotarget, 2017 8(7):10931-10944
- Sci Rep, 2017 7:46064
- J Immunol, 2017 198(8):3181-3194
- PLoS Comput Biol, 2017 13(3):e1005432
- J Allergy Clin Immunol, 2016 138(3):839-851
- Cell Death Differ, 2016 23(4):628-39
- Leukemia, 2016 30(5):1116-25
- Cancer Res, 2016 76(23):6937-6949
- PLoS Pathog, 2016 12(3):e1005487
- J Invest Dermatol, 2016 136(1):192-201
- PLoS Genet, 2016 12(9):e1006279
- PLoS One, 2016 11(10):e0164895
- Leukemia, 2015 29(6):1350-9
- Mol Syst Biol, 2015 11(1):789
- J Leukoc Biol, 2015 10.1189/jlb.3HI0814-371RR
- Sci Rep, 2015 5:16995
- J Biomol Screen, 2015 10.1177/1087057115585724
- Nat Commun, 2014 5:5444
- J Clin Invest, 2014 124(11):5074-84
- Eur J Med Chem, 2014 86C:664-675
- J Bone Miner Res, 2014 29(12):2618-35
- Eur J Immunol, 2014 44(12):3729-40
- Exp Cell Res, 2014 322(1):99-107
- PLoS One, 2014 9(5):e96703
- Exp Dermatol, 2014 23(12):884-9
- Int J Dev Biol, 2014 58(10-12):811-8
- Clin Cancer Res, 2013 19(3):586-97
- Br J Haematol, 2013 163(5):590-602
- UVIC, 2013 Meritxell Aguiló García
化学信息&溶解度
分子量 | 628.63 |
分子式 | C22H23FN6O5.C6H6O3S |
CAS号 | 841290-81-1 |
Smiles | CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)O |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 159.07 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : 0 mg/mL DMSO : 126 mg/mL ( 200.43 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 8 mg/mL Water : Insoluble DMSO : 100 mg/mL ( 159.07 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 38 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
Corn oil
浓度:0.5mg/ml
(0.80mM)
操作示例:以 1 mL 工作液为例,取50μL120mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。